ABSTRACT
In the past decade the incidence of lung cancer among women has risen, whereas among men it has slightly declined. Important differences in lung cancer have been demonstrated between men and women, although many areas still remain controversial. Some biologic differences may justify the increase in response of women to therapy for lung cancer and can partially explain the improved survival of women compared with men. We extensively reviewed the published scientific literature on this topic in order to investigate the clinical and genetic profiling underlying lung cancer in women and to use this information as a tool for medical therapy.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Lung Neoplasms/drug therapy , Lung Neoplasms/etiology , Antibodies, Monoclonal/pharmacology , Antineoplastic Agents/pharmacology , Chemotherapy, Adjuvant , Clinical Trials as Topic , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Female , Genetic Predisposition to Disease , Hormone Replacement Therapy , Humans , Lung Neoplasms/epidemiology , Lung Neoplasms/physiopathology , Male , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/metabolism , Risk Factors , Smoking , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/metabolismABSTRACT
OBJECTIVE: The attempt to improve therapeutic results in pancreatic carcinoma has recently focused on the emerging role of molecular biology. We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer. METHODS: Forty-four patients with histologically or cytologically verified, locally advanced unresectable and/or metastatic pancreatic carcinoma were eligible for the study. RESULTS: Thirty-three patients (75%) assumed celecoxib for all their treatment period. Treatment was repeated every 2 weeks, until there was evidence of disease progression, patient refusal, or unacceptable toxicity. Efficacy was assessed according to tumor response, clinical benefit, and time-related parameters. Five patients had a partial response, 24 had a stable disease, and 15 had a disease progression, for an overall response rate of 11%. Biochemical response rate based on CA 19.9 levels showed 2 complete and 10 partial responses, whereas 31 patients presented no changes of CA 19.9 levels. COX-2 protein expression was found in 30 tumors, while a moderate or weak/absent expression was present in 10 patients. Sixteen tumors showed a strong expression for NF-KB, 4 a moderate expression, and 5 a weak/absent expression. CONCLUSION: The use of a COX-2 inhibitor does not add any valuable activity to a gemcitabine/oxaliplatin combination, even in patients with COX-2 and NF-KB overexpressing tumors.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclooxygenase 2 Inhibitors/therapeutic use , Cyclooxygenase 2/genetics , NF-kappa B/genetics , Pancreatic Neoplasms/drug therapy , Adult , Aged , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/toxicity , Celecoxib , Cyclooxygenase 2 Inhibitors/toxicity , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Male , Middle Aged , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/genetics , Patient Selection , Predictive Value of Tests , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Treatment Outcome , GemcitabineABSTRACT
Chemotherapy is of crucial importance in advanced gastric cancer patients, in order to obtain palliation of symptoms and improve survival. The most extensively studied drugs as single agents are 5-fluorouracil, cisplatin, doxorubicin, epirubicin, mitomycin C and etoposide. Newer chemotherapeutic agents include the taxanes (docetaxel and paclitaxel), oral fluoropyrimidines (capecitabine and S-1), oxaliplatin and irinotecan. Randomised trials comparing monotherapy with combination regimens have consistently shown increased response rates in favour of combination regimens, whereas only marginally improved survival rates were usually found. Several combination therapies have been developed and have been examined in Phase III trials. However, in most cases, they have failed to demonstrate a survival advantage over the reference arm. There is no internationally accepted standard of care, and uncertainty remains regarding the choice of the optimal chemotherapy regimen. The objective of this article is to review the present literature available on major Phase II - III clinical trials, in which patients suffering from advanced gastric cancer were treated with cytotoxic chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Patient Care/standards , Stomach Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Disease-Free Survival , Humans , Stomach Neoplasms/mortalitySubject(s)
Adenocarcinoma/therapy , Neoadjuvant Therapy , Pancreatic Neoplasms/therapy , Adenocarcinoma/mortality , Chemotherapy, Adjuvant/methods , Chemotherapy, Adjuvant/trends , Combined Modality Therapy/methods , Combined Modality Therapy/trends , Humans , Neoadjuvant Therapy/methods , Neoadjuvant Therapy/trends , Pancreatectomy , Pancreatic Neoplasms/mortality , Pancreaticoduodenectomy , Radiotherapy, Adjuvant/methods , Radiotherapy, Adjuvant/trends , Survival RateABSTRACT
AIMS AND BACKGROUND: Colorectal cancer is the most common gastrointestinal tumor in Western countries and is increasing in elderly patients. In recent years, new treatments based on the use of 5-fluorouracil associated with oxaliplatin or CPT-11 have shown promising activity. The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer. METHODS: Patients aged 70 years or older with advanced colorectal cancer were treated with 5-fluorouracil (400 mg/m2 in bolus and 600 mg/m2 in a 22-hr continuous infusion on days 1-2) plus folinic acid (100 mg/m2) associated to oxaliplatin (85 mg/m2 on day 1, FOLFOX regimen) or CPT-11 (180 mg/m2 on day 1, FOLFIRI regimen), every 14 days. RESULTS: Twenty-nine patients with a median age of 76 years (range, 70-82) were treated with FOLFOX or FOLFIRI as first-line chemotherapy for metastatic disease. We observed a partial response in 8/29 (27.6%), stable disease in 11/29 (37.9%) and progressive disease in 10/29 (34.5%). Median survival was 21 months; 1-year survival probability was 89.8%. Grade III leukopenia was observed in 2/29 (7%) patients and grade III diarrhea in 1/29 patients. No other grade III-IV toxicity was observed. CONCLUSIONS: FOLFOX and FOLFIRI appear to be active and well tolerated regimens for elderly patients with advanced colorectal cancer.